Generic-Drug Co. Wants Gout Drug Antitrust Suit Tossed
By Matthew Santoni ( November 2, 2021, 7:06 PM EDT) -- Drugmaker Par Pharmaceutical Inc. told a Pennsylvania federal court it could not have participated in an alleged conspiracy to delay a generic version of Takeda Pharmaceuticals' anti-gout drug Colcrys because the FDA did not authorize Par's own version of the drug until this summer....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.